Oseltamivir

Generic Name
Oseltamivir
Brand Names
Ebilfumin, Tamiflu
Drug Type
Small Molecule
Chemical Formula
C16H28N2O4
CAS Number
196618-13-0
Unique Ingredient Identifier
20O93L6F9H
Background

Oseltamivir (marketed as the product TamifluⓇ), is an antiviral neuraminidase inhibitor used for the treatment and prophylaxis of infection with influenza viruses A (including pandemic H1N1) and B. Oseltamivir exerts its antiviral activity by inhibiting the activity of the viral neuraminidase enzyme found on the surface of the virus, which prevents budding f...

Indication

According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours . In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms ...

Associated Conditions
Flu caused by Influenza, Influenza A Virus Infection, Influenza A, Influenza B, Influenza Type B
Associated Therapies
-
Clinical Trials
Related News

Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults

Phase 1
Completed
Conditions
Influenza
Virus Diseases
Interventions
Drug: Zanamivir
Drug: Oseltamivir
First Posted Date
2009-06-16
Last Posted Date
2010-03-19
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
17
Registration Number
NCT00921726
Locations
🇹🇭

Mathidol University, Salaya, Thailand

Influenza Resistance Information Study

Completed
Conditions
Influenza
Interventions
Drug: Oseltamivir
First Posted Date
2009-04-20
Last Posted Date
2016-10-19
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
4561
Registration Number
NCT00884117

Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection

First Posted Date
2009-01-27
Last Posted Date
2010-09-30
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
60
Registration Number
NCT00830323
Locations
🇫🇷

Hospices civils de Lyon, Lyon, France

Oseltamivir Randomised Controlled Efficacy Trial

First Posted Date
2008-07-01
Last Posted Date
2018-06-06
Lead Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Target Recruit Count
1190
Registration Number
NCT00707941
Locations
🇧🇩

Kamalapur Urban Site, ICDDR,B, Dhaka, Bangladesh

Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age

Phase 4
Completed
Conditions
Influenza
Interventions
Drug: oseltamivir
Drug: placebo
First Posted Date
2008-01-15
Last Posted Date
2009-06-19
Lead Sponsor
Hospital District of Southwestern Finland
Target Recruit Count
409
Registration Number
NCT00593502
Locations
🇫🇮

Turku University Hospital, Turku, Finland

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

Not Applicable
Completed
Conditions
Influenza
Interventions
Drug: Placebo
Drug: Oseltamivir
First Posted Date
2007-11-09
Last Posted Date
2018-10-16
Lead Sponsor
Marshfield Clinic Research Foundation
Target Recruit Count
194
Registration Number
NCT00555893
Locations
🇺🇸

Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Phase 3
Completed
Conditions
Influenza, Human
Interventions
Drug: oseltamivir
Other: placebo
First Posted Date
2007-10-17
Last Posted Date
2018-07-12
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
228
Registration Number
NCT00545532
Locations
🇺🇸

Baylor University Medical Center Transplant Administration, Dallas, Texas, United States

🇺🇸

Sammons Cancer Center-Baylor University; Blood & Marrow Transplantation, Dallas, Texas, United States

🇺🇸

UCLA Medical center Medicine/Nephrology, Los Angeles, California, United States

and more 205 locations

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

First Posted Date
2007-03-29
Last Posted Date
2015-02-12
Lead Sponsor
BioCryst Pharmaceuticals
Target Recruit Count
137
Registration Number
NCT00453999
Locations
🇺🇸

Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States

🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 80 locations

Pharmacologic Study of Oseltamivir in Healthy Volunteers

Phase 1
Completed
Conditions
Avian Influenza A Virus
First Posted Date
2007-02-23
Last Posted Date
2009-07-28
Lead Sponsor
Mahidol University
Target Recruit Count
21
Registration Number
NCT00439530
Locations
🇹🇭

Bangkok Hospital for Tropical Diseases Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

Phase 4
Completed
Conditions
Influenza
Interventions
Drug: Oseltamivir
Drug: Placebo
First Posted Date
2006-12-18
Last Posted Date
2016-06-10
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
477
Registration Number
NCT00412737
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy